Morphic Therapeutic Inc.

Address: Lilly Corporate Center

Sponsor Overview

assignment

Specializations

Inflammatory Bowel Disease

Morphic Therapeutic Inc. focuses its clinical research on inflammatory bowel disease, with studies centered on adults living with moderately to severely active Crohn’s disease and moderately to severely active ulcerative colitis. The sponsor’s trial portfolio is directed toward gastrointestinal inflammation and disease control in these chronic conditions.

Crohn’s disease
Ulcerative colitis
Gastrointestinal inflammation

Clinical activity spans multiple countries and collaborating research sites, reflecting an active development program in gastroenterology.

Endoscopic Disease Assessment

Research conducted by the sponsor includes evaluation of endoscopic response as a key area of interest, indicating attention to visible inflammatory changes in the intestinal tract. This aligns with clinical assessment of mucosal disease activity in IBD.

Endoscopic response
Mucosal inflammation
Intestinal healing

These studies are designed around measurable outcomes relevant to the structural and inflammatory features of bowel disease.

Clinical Remission and Symptom Control

The sponsor’s research also emphasizes clinical remission in ulcerative colitis and Crohn’s disease, highlighting interest in improving symptom burden and day-to-day disease activity for patients with chronic intestinal inflammation.

Clinical remission
Symptom control
Disease activity

Trial objectives in this area focus on patient-centered outcomes that reflect reduced inflammatory impact in gastrointestinal disease.

Histologic Improvement

Another therapeutic interest is histologic improvement, showing attention to tissue-level inflammation and repair in ulcerative colitis. This area of research supports assessment of microscopic disease features alongside clinical signs and endoscopic findings.

Histologic improvement
Tissue inflammation
Colonic mucosa

The sponsor’s studies connect pathological assessment with broader management of immune-mediated intestinal disease.

Trial Name	Country	Status
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-2)	Austria Bulgaria Czechia Estonia France Germany Hungary Italy Latvia Lithuania Poland Romania Slovakia	Not Recruiting
Evaluation of MORF-057 Efficacy and Safety in Adults with Moderately to Severely Active Crohn's Disease: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study	Austria Bulgaria Croatia Czechia Estonia France Germany Hungary Italy Latvia Poland Romania Slovakia Spain	Recruiting
Evaluation of MORF-057 Efficacy, Safety, and Tolerability in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2a Open-label Study	Poland	Not Recruiting